A Study of SGN-ALPV in Advanced Solid Tumors

Inclusion Criteria: * Participants must have one of the following histologically or cytologically confirmed metastatic or unresectable solid tumor types: * Parts A and B * Ovarian cancer * Endometrial cancer * Non-small cell lung cancer (NSCLC) * Gastric cancer, including gastroesophageal junction (GEJ) carcinoma * Cervical cancer * Malignant testicular germ cell tumor (GCT), except for pure teratomas * Malignant ovarian GCT, except for pure teratomas * Malignant extragonadal GCT except for pure teratomas or tumors with primaries arising from CNS * Part C * High-grade serous ovarian cancer (HGSOC): Participants must have HGSOC which has progressed or relapsed within 6 months after previous platinum containing chemotherapy, received 2 to 4 prior anticancer lines of therapy, and at least 1 line of therapy in the platinum-resistant setting. If eligible at least 1 line of therapy must have contained bevacizumab or a biosimilar to bevacizumab. * Endometrial Cancer: Participants must have unresectable locally advance or metastatic endometrial carcinoma and have had at least 1 prior line of therapy. * NSCLC: Participants must have unresectable locally advanced or metastatic NSCLC and have received platinum-based therapy and a PD-(L)1 inhibitor. * Gastric cancer or GEJ carcinoma: Participants must have unresectable locally advanced or metastatic gastric cancer or GEJ carcinoma and have received prior platinum and fluoropyrimidin…